4-phenylbutyric acid has been researched along with HbS Disease in 4 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Odièvre, MH | 1 |
| Brun, M | 1 |
| Krishnamoorthy, R | 1 |
| Lapouméroulie, C | 1 |
| Elion, J | 1 |
| Dover, GJ | 2 |
| Brusilow, S | 1 |
| Charache, S | 1 |
| Collins, AF | 1 |
| Pearson, HA | 1 |
| Giardina, P | 1 |
| McDonagh, KT | 1 |
| Brusilow, SW | 1 |
| Fibach, E | 1 |
| Prasanna, P | 1 |
| Rodgers, GP | 1 |
| Samid, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 4-phenylbutyric acid and HbS Disease
| Article | Year |
|---|---|
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Erythropoietin; Female; Fetal Hemog | 1995 |
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Erythropoietin; Female; Fetal Hemog | 1995 |
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Erythropoietin; Female; Fetal Hemog | 1995 |
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Blood Transfusion; Erythropoietin; Female; Fetal Hemog | 1995 |
3 other studies available for 4-phenylbutyric acid and HbS Disease
| Article | Year |
|---|---|
Sodium phenyl butyrate downregulates endothelin-1 expression in cultured human endothelial cells: relevance to sickle-cell disease.
Topics: Anemia, Sickle Cell; Cell Line, Transformed; Drug Evaluation, Preclinical; Drug Synergism; Endotheli | 2007 |
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Female; Fetal Hemoglobin; Humans; Male | 1994 |
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Topics: Anemia, Sickle Cell; Azacitidine; beta-Thalassemia; Blotting, Northern; Butyrates; Butyric Acid; Cel | 1993 |